NFSG
FDMT icon

Newbridge Financial Services Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Newbridge Financial Services Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-30
Closed -$382 – 1223
2023
Q3 		$382 Hold
30
– – ﹤0.01% 1217
2023
Q2 		$542 Hold
30
– – ﹤0.01% 1257
2023
Q1 		$516 Hold
30
– – ﹤0.01% 1319
2022
Q4 		$666 Hold
30
– – ﹤0.01% 1340
2022
Q3 		$0 Hold
30
– – ﹤0.01% 1412
2022
Q2 		$0 Hold
30
– – ﹤0.01% 1406
2022
Q1 		$0 Hold
30
– – ﹤0.01% 1475
2021
Q4 		$1K Hold
30
– – ﹤0.01% 1320
2021
Q3 		$1K Hold
30
– – ﹤0.01% 1253
2021
Q2 		$1K Hold
30
– – ﹤0.01% 1350
2021
Q1 		$1K Buy
+30
New +$1.33K ﹤0.01% 1267

Other funds holding FDMT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Newbridge Financial Services Group's FDMT Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of 4D Molecular Therapeutics (FDMT) in Q4 2023, closing a stake of 30 shares — an estimated $382 sold.

Newbridge Financial Services Group first reported a position in FDMT in Q1 2021 and held it in 11 quarters. The position peaked at $1K in Q4 2021. 111 funds tracked by Wall St. Rank hold FDMT as of Q4 2023.

  • Newbridge Financial Services Group reported no remaining 4D Molecular Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Newbridge Financial Services Group sold 30 4D Molecular Therapeutics shares in Q4 2023, an estimated $382.
  • Newbridge Financial Services Group first reported a position in 4D Molecular Therapeutics in Q1 2021 and held it in 11 quarters.
  • Newbridge Financial Services Group's 4D Molecular Therapeutics position peaked at $1K in Q4 2021.
  • 111 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.